Histological scores and tumor size on stage II in adrenocortical carcinomas
Rui Caetano Oliveira,
Maria João Martins,
Carolina Moreno,
Rui Almeida,
João Carvalho,
Paulo Teixeira,
Miguel Teixeira,
Edgar Tavares Silva,
Isabel Paiva,
Arnaldo Figueiredo,
Maria Augusta Cipriano
Affiliations
Rui Caetano Oliveira
Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Maria João Martins
Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal
Carolina Moreno
Endocrinology, Diabetes and Metabolism Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Rui Almeida
Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal
João Carvalho
Urology and Renal Transplantation, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Paulo Teixeira
Pathology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Miguel Teixeira
Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Coimbra, Portugal
Edgar Tavares Silva
Urology and Renal Transplantation, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Isabel Paiva
Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal
Arnaldo Figueiredo
Urology and Renal Transplantation, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Maria Augusta Cipriano
Pathology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Adrenocortical carcinomas (ACC) are aggressive tumors with a poor prognosis. Histological scores are advised for the diagnosis, however, there are borderline cases that may be misjudged as adrenocortical adenomas (ACA). The three main scores used are: Weiss Modified System (WMS), Reticulin Algorithm (RA), and Helsinki Score (HS). We intend to compare the accuracy of the three scores in ACC diagnosis and to identify predictive factors of overall survival (OS). Retrospective study (2004–2016) at Centro Hospitalar e Universitário de Coimbra of the adrenal tumors, classified as ACC or ACA, with a history of posterior tumor relapse/metastases, without lesions in the contralateral adrenal gland: 13F and 6M, with a median age of 51 ± 12.41 years. Nodules’ median size was 9.20 ± 6.2 cm. Patients had a median OS of 52 ± 18.6 months, with 57.9% and 46.3%, at 3 and 5 years. Seven patients had local recurrence and nine had metastases. Thirteen cases were in stage II. The WMS and the HS allowed a diagnosis of ACC in 15 cases and the RA defined ACC in 17 cases. All cases had, at least, focal disruption of the reticulin framework. More than 5 mitosis/50 HPF was associated with worse OS: 49.67 ± 21.43 versus 108.86 ± 14.02 months ( p = 0.026). In patients with stage II, tumor size ⩾10 cm was associated with worse OS: 19.25 ± 7.15 versus 96.11 ± 16.7 months ( p = 0.007), confirmed by multivariate analysis ( p = 0.031). The correct diagnosis of ACC is a pathologist responsibility. The RA seems the most accurate. Any loss of the reticulin framework should raise awareness for malignancy. In patients on stage II, a size ⩾10 cm is a predictor of worse prognosis.